Hussman Strategic Advisors’s Meridian Bioscience Inc VIVO Stock Holding History

Hussman Strategic Advisors’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-46,500	Closed	-$1.47M	–	322
2022 Q3	$1.47M	Sell	46,500 -15,500	-25%	-$502K	0.25%	164
2022 Q2	$1.89M	Buy	+62,000	New	+$1.68M	0.33%	111
2021 Q4	–	Sell	-144,000	Closed	-$2.77M	–	359
2021 Q3	$2.77M	Hold	144,000	–	–	0.61%	37
2021 Q2	$3.19M	Hold	144,000	–	–	0.66%	31
2021 Q1	$3.78M	Buy	144,000 +16,000	+13%	+$380K	0.78%	13
2020 Q4	$2.39M	Buy	128,000 +77,000	+151%	+$1.44M	0.63%	46
2020 Q3	$866K	Buy	+51,000	New	+$991K	0.23%	165
2014 Q4	–	Sell	-7,500	Closed	-$133K	–	226
2014 Q3	$133K	Hold	7,500	–	–	0.01%	184
2014 Q2	$155K	Sell	7,500 -7,500	-50%	-$154K	0.01%	165
2014 Q1	$327K	Buy	15,000 +5,000	+50%	+$115K	0.02%	168
2013 Q4	$265K	Sell	10,000 -2,500	-20%	-$61.4K	0.02%	169
2013 Q3	$296K	Hold	12,500	–	–	0.02%	166
2013 Q2	$269K	Buy	+12,500	New	+$270K	0.01%	181

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hussman Strategic Advisors's VIVO Position: Q4 2022 in Review

Hussman Strategic Advisors sold out of Meridian Bioscience Inc (VIVO) in Q4 2022, closing a stake of 46,500 shares — an estimated $1.47M sold.

Hussman Strategic Advisors first reported a position in VIVO in Q2 2013 and held it in 13 quarters. The position peaked at $3.78M in Q1 2021. 218 funds tracked by Wall St. Rank hold VIVO as of Q4 2022.

Hussman Strategic Advisors reported no remaining Meridian Bioscience Inc position as of Q4 2022 after selling out during the quarter.
Hussman Strategic Advisors sold 46,500 Meridian Bioscience Inc shares in Q4 2022, an estimated $1.47M.
Hussman Strategic Advisors first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 13 quarters.
Hussman Strategic Advisors's Meridian Bioscience Inc position peaked at $3.78M in Q1 2021.
218 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2022.

Based on Hussman Strategic Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.